Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AUR 104

Next Previous
Drug Profile

AUR 104

Alternative Names: AUR-104; XL-114

Latest Information Update: 14 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aurigene Discovery Technologies
  • Developer Aurigene Oncology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action FABP5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic lymphocytic leukaemia; Hodgkin's disease; Non-Hodgkin's lymphoma
  • Preclinical Solid tumours

Most Recent Events

  • 14 Jul 2026 AUR 104 is still in preclinical trials for Solid tumours in India (PO) (Aurigene Oncology pipeline, July 2026)
  • 14 Apr 2026 Aurigene Oncology terminates the phase I VIJAY-1 trial in Non-Hodgkin's lymphoma, Chronic lymphocytic leukaemia and Hodgkin's disease (Second-line therapy or greater) in India (PO, Tablet) due to patient recruitment problems (NCT06761586)
  • 28 Nov 2025 No recent reports of development identified for preclinical development in Solid-tumours in India (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top